Co-Diagnostics, Inc.

CODX Healthcare Medical Devices

Co-Diagnostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $622,500.00, down 84.1% from fiscal 2024. In the quarter to June 2026, revenue grew 1.96%, EPS grew 78.9% and free cash flow grew 17.5%, each against the same quarter a year earlier.

0.65 0.07 −9.72%
Market cap
$5.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
2/9
Altman Z
−9.74
Beneish M
2.24
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 2 2 2

+8 more TTM periods

ROE
(174.77%) (151.66%) (125.89%) (62.12%)
ROA
(149.25%) (126.56%) (106.21%) (54.95%)
ROIC
(337.68%) (406.63%) (358.57%) (78.24%)
Return on Tangible Assets
(1,093.26%) (633.49%) (377.40%) (250.49%)
Average Days of Receivables
26.56 41.88 137.73 703.63
Free Cash Flow per Share
(6.37) (12.86) (22.43) (25.21)
Free Cash Flow
(27.47) (28.99) (29.84) (31.81)
Other line items

Show all line items

Columns are period end dates